Barclays
PRAX icon

Barclays’s Praxis Precision Medicines PRAX Stock Holding History

Barclays’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Sell
6,095
-884
-13% -$280K ﹤0.01% 2327
2026
Q1 		$2.25M Sell
6,979
-523,772
-99% -$162M ﹤0.01% 2286
2025
Q4 		$156M Buy
530,751
+454,114
+593% +$84.6M 0.04% 344
2025
Q3 		$4.06M Sell
76,637
-12,087
-14% -$586K ﹤0.01% 2356
2025
Q2 		$3.73M Buy
88,724
+56,956
+179% +$2.17M ﹤0.01% 2351
2025
Q1 		$1.2M Sell
31,768
-5,520
-15% -$345K ﹤0.01% 2996
2024
Q4 		$2.87M Buy
37,288
+158
+0.4% +$11.4K ﹤0.01% 2618
2024
Q3 		$2.14M Buy
37,130
+20,759
+127% +$1.12M ﹤0.01% 2799
2024
Q2 		$677K Sell
16,371
-74
-0.4% -$3.5K ﹤0.01% 2837
2024
Q1 		$1M Buy
16,445
+7,200
+78% +$323K ﹤0.01% 3118
2023
Q4 		$206K Buy
+9,245
New +$167K ﹤0.01% 4405
2023
Q2 		– Sell
-1,611
Closed -$19.6K – 4975
2023
Q1 		$19.6K Buy
1,611
+908
+129% +$38.3K ﹤0.01% 4662
2022
Q4 		$25.1K Buy
703
+596
+557% +$18.6K ﹤0.01% 4763
2022
Q3 		$4K Sell
107
-20
-16% -$997 ﹤0.01% 4541
2022
Q2 		$5K Sell
127
-240
-65% -$25.6K ﹤0.01% 4787
2022
Q1 		$56K Buy
+367
New +$75.4K ﹤0.01% 4068

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Barclays's PRAX Position: Q2 2026 in Review

Barclays reduced its Praxis Precision Medicines (PRAX) stake by 13% in Q2 2026, selling an estimated $280K and leaving 6,095 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

Barclays first reported a position in PRAX in Q1 2022 and has held it in 16 quarters since. The position peaked at $156M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Barclays held 6,095 shares of Praxis Precision Medicines worth $2.04M as of Q2 2026.
  • Barclays sold 884 Praxis Precision Medicines shares in Q2 2026, an estimated $280K.
  • Praxis Precision Medicines made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2327 holding.
  • Barclays first reported a position in Praxis Precision Medicines in Q1 2022 and has held it in 16 quarters since.
  • Barclays's Praxis Precision Medicines position peaked at $156M in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.